Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection
- Jonathan A. Bock
- , Kimberly J. Fairley
- , Robert E. Smith
- , Daniel D. Maeng
- , James M. Pitcavage
- , Nicholas A. Inverso
- , Marc S. Williams
Research output: Contribution to journal › Article › peer-review
3
Link opens in a new tab
Scopus
citations